Novartis Reports Results of Kisqali in P-III MONALEESA-7 Trial to Treat HR+/HER2- Metastatic Breast Cancer

December 10, 2020 Auto Bot Clinical Trials, Novartis, P-III, reports, results 0

Shots:

  • The P-III MONALEESA-7 trial involves assessing Kisqali + endocrine therapy (goserelin + either an aromatase inhibitor or tamoxifen) as initial treatment vs endocrine therapy alone in patients with HR+/HER2- m-BC
  • Result: @53.5 mos. follow-up, m-OS (58.7 vs 48.0 mos.); similar m-OS (58.7 vs 47.7 mos.) observed in IIT population; @ 42 mos. follow-up, estimated survival rate (70.2% vs 46%)
  • The US FDA and EC has approved Kisqali in Mar’2017 and Aug’2017 as initial endocrine-based therapy for postmenopausal women with HR+/HER2- LA/m-BC in combination with an aromatase inhibitor based on findings from the pivotal MONALEESA-2 trial

Click here to­ read the full press release/ article | Ref: PRNewswire | Image: BioProcess International

The post Novartis Reports Results of Kisqali in P-III MONALEESA-7 Trial to Treat HR+/HER2- Metastatic Breast Cancer first appeared on PharmaShots.